Collegium Pharmaceutical, Inc. COLL Belbuca — Finite-Lived Intangible Assets, Accumulated Amortization
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, accumulated amortization?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — finite-lived intangible assets, accumulated amortization of $303.46M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, accumulated amortization changed year-over-year?
- Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, accumulated amortization increased by 33.1% year-over-year, from $228.06M to $303.46M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, accumulated amortization?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, accumulated amortization has grown at a 104.1% compound annual growth rate (CAGR), from $120.68M to $1.03B.
- What does belbuca — finite-lived intangible assets, accumulated amortization mean?
- The cumulative amount of amortization expense recognized for Belbuca-related intangible assets since their acquisition or capitalization. This metric tracks the historical consumption of the asset's economic value over its useful life.